Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.

Xenobiotica; the fate of foreign compounds in biological systems 20130501

Pazopanib: in advanced soft tissue sarcoma.

Drugs 20121112

An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.

European journal of cancer (Oxford, England : 1990) 20121101

Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.

Circulation 20121030

Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.

International journal of pharmaceutics 20121015

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120915

Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.

Pediatric blood & cancer 20120901

A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20120901

Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.

Retina (Philadelphia, Pa.) 20120901

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.

The Journal of clinical endocrinology and metabolism 20120901

Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.

Expert opinion on drug safety 20120901

Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.

Annals of oncology : official journal of the European Society for Medical Oncology 20120901

[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].

Magyar onkologia 20120901

Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.

Expert review of anticancer therapy 20120901

Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases.

Chemical communications (Cambridge, England) 20120825

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.

British journal of cancer 20120807

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.

Investigational new drugs 20120801

A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.

Investigational new drugs 20120801

Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.

Molecular cancer therapeutics 20120801

Concise drug review: pazopanib and axitinib.

The oncologist 20120801

Biomarkers in personalised treatment of renal-cell carcinoma.

The Lancet. Oncology 20120801

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

The Lancet. Oncology 20120801

Antiangiogenic treatment in metastatic urothelial cancer.

The Lancet. Oncology 20120801

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

The Lancet. Oncology 20120801

[Soft-tissue sarcoma: recent developments].

Deutsche medizinische Wochenschrift (1946) 20120801

Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS).

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120715

Targeted therapies: pazopanib for soft-tissue sarcoma: a PALETTE of data emerges.

Nature reviews. Clinical oncology 20120703

Decade of molecular targeted therapy: abdominal manifestations of drug toxicities--what radiologists should know.

AJR. American journal of roentgenology 20120701

Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report.

Targeted oncology 20120601

Current treatment considerations in metastatic renal cell carcinoma.

Current treatment options in oncology 20120601

Pazopanib in the treatment of soft tissue sarcoma.

Expert review of anticancer therapy 20120601

Rapid analysis of whole blood by paper spray mass spectrometry for point-of-care therapeutic drug monitoring.

The Analyst 20120521

Pazopanib and the treatment palette for soft-tissue sarcoma.

Lancet (London, England) 20120519

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Lancet (London, England) 20120519

Novel molecular targeted therapies for refractory thyroid cancer.

Head & neck 20120501

Targeted therapeutic strategies for the management of renal cell carcinoma.

Current opinion in oncology 20120501

[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11)].

Der Urologe. Ausg. A 20120501

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.

Journal of cancer research and clinical oncology 20120401

Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120310

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

Prostate cancer and prostatic diseases 20120301

Pazopanib for the treatment of metastatic renal cell carcinoma.

Clinical therapeutics 20120301

[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].

Magyar onkologia 20120301

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group.

British journal of cancer 20120214

Second-line treatment for renal cell cancer.

British journal of cancer 20120214

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.

European journal of cancer (Oxford, England : 1990) 20120201

Pazopanib for the treatment of breast cancer.

Expert opinion on investigational drugs 20120201

Nursing considerations for patients receiving pazopanib for renal cell carcinoma.

ONS connect 20120201

Targeted therapies for renal cell carcinoma: review of adverse event management strategies.

Journal of the National Cancer Institute 20120118

An update on targeted therapy in metastatic renal cell carcinoma.

Urologic oncology 20120101

Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.

Journal of biochemistry 20120101

Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.

Oncology 20120101

[Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].

Revue medicale de Liege 20120101

Reversible posterior leukoencephalopathy syndrome induced by pazopanib.

BMC cancer 20120101

Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.

Clinical genitourinary cancer 20111201

Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.

Future oncology (London, England) 20111201

Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.

The Canadian journal of urology 20111201

Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.

Clinical cancer research : an official journal of the American Association for Cancer Research 20111101

Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage.

Microvascular research 20111101

The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

Clinical cancer research : an official journal of the American Association for Cancer Research 20111101

Tyrosine kinase inhibitors for metastatic renal cell carcinoma.

Drug and therapeutics bulletin 20111101

[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].

Bulletin du cancer 20111001

Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.

Clinical journal of oncology nursing 20111001

Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.

Urology 20111001

[Dermatologic side effects induced by new angiogenesis inhibitors].

Bulletin du cancer 20111001

Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.

European journal of pharmacology 20110901

Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110901

[Pharmacological sheet: pazopanib (Votrient), oral administration].

Journal de pharmacie de Belgique 20110901

A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110815

Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.

Hematology/oncology clinics of North America 20110801

Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.

The Canadian journal of urology 20110801

[Systemic treatment of renal cell carcinoma - recent update].

Wiener medizinische Wochenschrift (1946) 20110801

Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.

Urology 20110701

[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

Aktuelle Urologie 20110701

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110620

Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma.

Journal of hepatology 20110601

Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.

Clinical therapeutics 20110601

Pazopanib for the treatment of renal cancer.

Expert opinion on pharmacotherapy 20110501

[Novelties in the treatment for advanced renal-cell cancer].

Orvosi hetilap 20110424

[Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].

Der Urologe. Ausg. A 20110401

[Treatment of metastatic renal cell carcinoma].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20110401

Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.

Drugs 20110305

Pazopanib: Clinical development of a potent anti-angiogenic drug.

Critical reviews in oncology/hematology 20110301

NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma.

The Lancet. Oncology 20110301

Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?

Prescrire international 20110301

Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication.

Clinics and research in hepatology and gastroenterology 20110201

Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110101

In pursuit of new anti-angiogenic therapies for cancer treatment.

Frontiers in bioscience (Landmark edition) 20110101

Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.

BMC cancer 20110101

Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101

The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.

PloS one 20110101

The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.

BMC cancer 20110101

Pazopanib in renal cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20101215

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

Toxicological sciences : an official journal of the Society of Toxicology 20101201

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro.

Toxicology and applied pharmacology 20101201

A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.

Molecular cancer therapeutics 20101201

A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.

Clinical pharmacology and therapeutics 20101201

Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.

The oncologist 20101201

[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].

Magyar onkologia 20101201

An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.

Clinical pharmacology and therapeutics 20101101

Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.

Expert opinion on biological therapy 20101101

The therapy of kidney cancer with biomolecular drugs.

Cancer treatment reviews 20101101

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.

Gynecologic oncology 20101001

Pazopanib: in advanced renal cell carcinoma.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20101001

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

The Lancet. Oncology 20101001

Kinase inhibitors for refractory thyroid cancers.

The Lancet. Oncology 20101001

Is advanced renal cell carcinoma becoming a chronic disease?

Lancet (London, England) 20100821

Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping.

Journal of pharmaceutical and biomedical analysis 20100801

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

Neuro-oncology 20100801

Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100801

Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity.

Toxicologic pathology 20100801

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.

The oncologist 20100801

Bar the windows but open the door to randomization.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100701

Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100701

Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100701

Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.

Journal of cellular biochemistry 20100701

The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.

Clinical cancer research : an official journal of the American Association for Cancer Research 20100701

Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape.

Nature reviews. Clinical oncology 20100701

Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.

The Annals of pharmacotherapy 20100601

[Antiangionic drugs in soft tissue sarcoma].

Bulletin du cancer 20100601

Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib.

Diabetes care 20100601

(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.

The oncologist 20100601

Effect of pazopanib on tumor microenvironment and liposome delivery.

Molecular cancer therapeutics 20100601

Pazopanib trial data cannot support first-line use.

Nature reviews. Urology 20100601

Everolimus and pazopanib: two new drugs for renal cell cancer.

The Medical letter on drugs and therapeutics 20100503

Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.

Expert review of anticancer therapy 20100501

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.

British journal of cancer 20100427

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Molecular cancer therapeutics 20100401

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

Molecular cancer therapeutics 20100401

Pazopanib in renal cell carcinoma.

Clinical advances in hematology & oncology : H&O 20100401

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.

Cancer research 20100315

StatBite: FDA oncology drug product approvals in 2009.

Journal of the National Cancer Institute 20100224

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100220

Prognostic factors in patients treated with VEGF-targeted therapies.

Clinical advances in hematology & oncology : H&O 20100201

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100120

Pazopanib.

Nature reviews. Drug discovery 20100101

New weapons against kidney cancer. Two recent drug options appear to extend survival for kidney cancer patients who can't tolerate existing medications.

DukeMedicine healthnews 20100101

New therapeutic strategies for renal cell carcinoma.

Urologic nursing 20100101

Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.

Oncogene 20091203

Tyrosine kinase inhibitors and the thyroid.

Best practice & research. Clinical endocrinology & metabolism 20091201

Pazopanib: therapeutic developments.

Expert opinion on pharmacotherapy 20091201

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.

British journal of cancer 20091117

Pazopanib: an antiangiogenic drug in perspective.

Future oncology (London, England) 20091101

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090910

Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.

Journal of pharmaceutical and biomedical analysis 20090908

Pazopanib for the treatment of renal cell carcinoma and other malignancies.

Drugs of today (Barcelona, Spain : 1998) 20090901

Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor.

Oncology (Williston Park, N.Y.) 20090801

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701

Phase I trial of pazopanib in patients with advanced cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.

Cancer 20090515

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).

Blood 20090507

Targeted therapies in metastatic renal cancer in 2009.

BJU international 20090501

Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib.

Archives of ophthalmology (Chicago, Ill. : 1960) 20090401

Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist.

International journal of cardiology 20090124

Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.

Current opinion in investigational drugs (London, England : 2000) 20081201

Novel drugs for renal cell carcinoma.

Expert opinion on investigational drugs 20081001

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.

Journal of medicinal chemistry 20080814

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.

Expert opinion on investigational drugs 20080201

New drugs for ovarian cancer.

Clinical advances in hematology & oncology : H&O 20080201

Signaling inhibitors in metastatic renal cell carcinoma.

Cancer journal (Sudbury, Mass.) 20080101

American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.

IDrugs : the investigational drugs journal 20070801

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Molecular cancer therapeutics 20070701

Pazopanib: a novel multitargeted tyrosine kinase inhibitor.

Current oncology reports 20070301

New treatment approaches in metastatic renal cell carcinoma.

Current opinion in urology 20060901